What Are Mucinous Cysts and Are They Cancerous?

Mucinous cysts are fluid-filled growths lined with mucin-producing cells that can develop in several organs, most commonly the pancreas, ovaries, and appendix. Most are not cancerous at the time they are discovered, but many are considered precancerous, meaning they carry a real risk of transforming into invasive cancer over time. That dual nature, usually benign yet potentially dangerous, is what makes them one of the trickier problems in modern medicine. Whether a specific mucinous cyst warrants surgery, surveillance, or nothing at all depends on where it is, how big it is, what it looks like on imaging, and what its cells are doing at the molecular level.

What Makes a Cyst “Mucinous”

The term “mucinous” refers to the thick, gel-like mucin protein that these cysts produce. Mucins are glycoproteins your body makes in many tissues, from the lining of your stomach to your airways, where they serve a protective, lubricating role. In mucinous cysts, the cells lining the cyst wall secrete mucin into the cyst cavity, which is why these growths tend to be filled with viscous, jelly-like fluid rather than the thin, watery fluid found in simpler cysts. This mucin production is both a defining feature and a diagnostic clue. When doctors sample the fluid from a pancreatic cyst, for example, they test for substances that help confirm it is mucinous rather than a harmless serous cyst that almost never becomes cancerous.

Mucinous cysts exist on a spectrum. At one end are benign mucinous cystadenomas, completely innocent growths that just happen to produce mucin. At the other end are mucinous cystadenocarcinomas, which are frank cancers. In between sit “borderline” tumors and lesions with varying degrees of dysplasia, a term that just means the cells are starting to look abnormal under a microscope without having yet invaded surrounding tissue. The clinical challenge is figuring out where on that spectrum a particular cyst falls, because the jump from low-grade abnormality to invasive cancer can take years or, occasionally, happen faster than expected.

Mucinous Cysts of the Pancreas

The pancreas is the organ where mucinous cysts get the most attention, largely because pancreatic cancer is so lethal and mucinous cysts are recognized precursors. Two main types dominate: mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs). They are biologically distinct despite both producing mucin.

MCNs occur almost exclusively in women and tend to arise in the body or tail of the pancreas. They are defined by the presence of an ovarian-type tissue layer beneath the cyst lining, a quirk that pathologists use to confirm the diagnosis. European guidelines recommend surgical removal for MCNs that are 4 cm or larger, that cause symptoms, or that show a suspicious mural nodule, which is a solid bump protruding from the cyst wall. Smaller MCNs without worrisome features can be watched with regular imaging, though lifelong surveillance is advised as long as the patient is healthy enough for surgery if things change.¹ The good news is that when MCNs are removed before they become invasive, long-term outcomes are excellent. In one large series, none of the 77 patients whose MCNs lacked an invasive component developed recurrence after surgery.² Another study reported 5- and 10-year survival rates around 97% for MCNs overall.³

IPMNs are different. They grow within the pancreatic duct system and are further classified by whether they involve the main duct, a side branch, or both. Main-duct IPMNs carry a higher malignancy risk, and side-branch IPMNs are more common and generally more indolent, though they are not risk-free. Both types are driven in large part by mutations in KRAS and GNAS, two genes that cooperate to push normal duct cells toward cyst formation and, eventually, toward the kind of high-grade dysplasia that precedes invasive pancreatic cancer.⁴ In mouse models, the combination of activated KRAS and mutant GNAS reliably produces cystic lesions resembling human IPMNs, and the dysplasia worsens over time.⁵

Warning Signs That Raise the Cancer Alarm

Not every mucinous cyst needs to come out surgically. Doctors use a set of features, categorized as “high-risk stigmata” and “worrisome features,” to gauge how likely a pancreatic mucinous cyst is to harbor advanced disease. A systematic review found that mural nodules 5 mm or larger, solid components that light up on contrast imaging, and positive cytology from a needle aspirate are among the strongest predictors of high-grade dysplasia or invasive cancer.⁶ Obstructive jaundice, a main pancreatic duct dilated to 10 mm or wider, and a cyst growing by 2.5 mm or more per year also raise concern substantially.⁷

The accumulation of these features matters, too. Having multiple high-risk stigmata or multiple worrisome features is associated with higher rates of advanced disease compared to having just one. The 2024 Kyoto guidelines incorporate these features into a scoring model that outperforms earlier guideline versions in distinguishing dangerous cysts from harmless ones.⁷ Still, no guideline is perfect. A comparison of three major guidelines found stark trade-offs between sensitivity and specificity: one set of guidelines caught nearly three-quarters of cancers but flagged many benign cysts for unnecessary surgery, while another missed over 90% of cancers but rarely recommended surgery for benign lesions.⁸ This is an area of active improvement, not a solved problem.

How Mucinous Cysts Are Diagnosed

Most pancreatic cysts, mucinous or otherwise, are found incidentally when someone gets a CT or MRI for an unrelated reason. Once a cyst is spotted, the imaging workup typically involves a combination of contrast-enhanced CT, MRI with a special pancreatic-duct sequence called MRCP, and endoscopic ultrasound (EUS). Each modality has strengths. EUS is particularly good at identifying mural nodules and other internal features that suggest aggressiveness. MRI is better than CT at detecting internal walls within the cyst, seeing connections to the pancreatic duct, and picking up multiple cysts.⁹ In practice, many patients get more than one imaging modality because the features that predict malignancy, like an enhancing solid component or a dilated duct, are best assessed with contrast-enhanced techniques.¹⁰

When EUS is performed, doctors can also pass a fine needle into the cyst and aspirate fluid for analysis. For years, the standard test on that fluid was carcinoembryonic antigen (CEA), a tumor marker. A high CEA level suggests the cyst is mucinous, but it only catches a portion of cases. A newer and simpler test, measuring glucose in the cyst fluid, has proven substantially more accurate. A meta-analysis across multiple studies found that low cyst-fluid glucose identified mucinous cysts with about 91% sensitivity, compared to only 56% for CEA, while both tests had similarly high specificity.¹¹ Remarkably, this can even be done with a standard bedside glucometer, making it a rapid, inexpensive addition to the diagnostic workup.¹²

The KRAS Connection and Why It Matters for Progression

At the molecular level, KRAS mutations are central to the progression story of pancreatic mucinous cysts. In MCNs, KRAS mutations are uncommon in low-grade lesions (found in only about 5% of cases with mild dysplasia) but present in the vast majority of cases that have progressed to higher-grade dysplasia. When researchers looked at individual tumors that had both low-grade and high-grade areas, the same KRAS mutation was present in both zones, suggesting the mutation arose early and drove the progression.¹³ This finding has practical implications. Molecular testing of cyst fluid for KRAS and GNAS mutations is increasingly used alongside imaging and CEA to help decide whether a cyst is mucinous and how concerning it is.

Meanwhile, the mucin proteins themselves offer diagnostic clues. In noninvasive pancreatic MCNs, a mucin called MUC5AC is consistently expressed, while MUC1 is absent. Only when the cyst has developed an invasive cancer component does MUC1 appear.¹⁴ MUC2, another mucin type, tends to show up in benign mucinous lesions more than in cancers and is a marker of intestinal-type differentiation.¹⁵ These mucin patterns are not yet part of routine clinical decision-making for most patients, but they help pathologists classify tumors after surgery and are subjects of ongoing research as potential biomarkers.

Mucinous Cysts of the Ovary

Mucinous ovarian tumors follow a similar benign-to-malignant spectrum. Most are benign cystadenomas, large fluid-filled cysts that can grow impressively before causing symptoms. A subset are classified as “borderline” mucinous tumors, sometimes called mucinous tumors of low malignant potential, which have cells that look more abnormal than a simple cystadenoma but have not invaded the surrounding tissue. At the far end are mucinous ovarian carcinomas, which are true cancers. Case series have documented progression from benign cystadenoma to borderline tumor within as little as five months in young women, reinforcing the idea that even initially benign mucinous ovarian cysts warrant follow-up.¹⁶

One crucial issue with mucinous ovarian tumors is determining whether they actually started in the ovary or spread there from somewhere else. Cancers from the colon, stomach, pancreas, and appendix can metastasize to the ovary and mimic a primary ovarian mucinous tumor. Distinguishing the two matters enormously for treatment, because a metastasis requires treating the original cancer, not just the ovary. The combination of tumor size, whether one or both ovaries are involved, and a panel of protein markers can classify these correctly about 90% of the time.¹⁷ This is something pathologists actively assess, and it occasionally changes the entire course of a patient’s care.¹⁸

For young women who want to preserve fertility, management of mucinous ovarian tumors can be conservative. In early-stage mucinous ovarian cancer (limited to one ovary), fertility-sparing surgery that removes the affected ovary while leaving the uterus and opposite ovary intact has shown survival rates comparable to more radical surgery, with five-year overall survival above 97%.¹⁹ For borderline mucinous tumors specifically, French guidelines recommend removing the affected ovary and fallopian tube rather than just shelling out the cyst, because cystectomy alone carries a higher risk of recurrence and may leave behind abnormal tissue.²⁰

Appendiceal Mucinous Neoplasms and Pseudomyxoma Peritonei

The appendix is another common site for mucinous neoplasms, and these carry a unique risk. Appendiceal mucinous neoplasms range from low-grade (LAMN) to high-grade (HAMN) to outright mucinous adenocarcinoma, with several other histologic subtypes recognized in current classification systems.²¹ Many appendiceal mucinous tumors are discovered incidentally during surgery for suspected appendicitis.

The signature complication of appendiceal mucinous neoplasms is pseudomyxoma peritonei (PMP), a condition in which the neoplasm ruptures and seeds the abdominal cavity with mucin-producing cells. PMP fills the abdomen with gelatinous mucin deposits, which can compress organs and cause progressive symptoms. Most cases of PMP trace back to the appendix, even when an ovarian mucinous tumor is also present; historically, the ovary was often blamed incorrectly.²² Treating PMP requires an aggressive surgical approach called cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC), which is now the standard of care.²³ Five-year survival after this combined treatment reaches about 60% overall, and in patients whose tumors are low-grade, it rises to around 72%.²⁴

Less Common Locations

Mucinous cystic neoplasms can also develop in the liver and biliary tract, though this is rare. Like their pancreatic counterparts, liver MCNs are considered premalignant, and complete surgical excision is recommended because focal cancerous transformation has been documented. In one small surgical series, two out of seven confirmed liver MCNs turned out to harbor invasive carcinoma, and the tumors ranged from about 3 cm to 20 cm in diameter.²⁵ These liver lesions are easily mistaken on imaging for simple cysts, abscesses, or even other cancers, making the correct diagnosis something that often only becomes clear after surgery.²⁶

In children, mucinous cystic neoplasms of any organ are extremely rare, but they do occur. Pediatric cases have been reported in both the liver and the pancreas. A recent case of a 17-year-old with a 10 cm MCN in the pancreatic tail illustrates the general approach: the cyst was sampled by endoscopic ultrasound, the fluid showed very high CEA and low glucose consistent with a mucinous lesion, and pathology after surgical removal confirmed low-grade dysplasia with negative margins.²⁷ Limited data in children makes management decisions harder, but the basic principles, resect when there is significant size or concern for progression, mirror the adult approach.

What Happens After Surgery

Long-term outcomes for resected mucinous cysts depend heavily on whether invasive cancer was present at the time of surgery. For pancreatic MCNs removed before invasion, the prognosis is outstanding, with essentially no recurrence and survival rates above 95% at both five and ten years.³ Once invasion is present, the picture darkens considerably. In one classic series, five of six patients surviving initial surgery for invasive pancreatic mucinous cystadenocarcinoma died of recurrence within five years.²

For IPMNs, post-surgical five-year overall survival is roughly 97%, though the disease-free survival rate is lower at around 81%, reflecting the fact that IPMNs can recur in other parts of the pancreas or that new IPMNs can develop in the remaining gland.²⁸ This is why patients who have had part of their pancreas removed for IPMN still need ongoing surveillance of the remaining organ.

Living Under Surveillance

Many people with small, low-risk mucinous pancreatic cysts are told they need regular imaging, sometimes for the rest of their lives. The psychological experience of this varies more than you might expect. One study found that patients under surveillance reported higher levels of anxiety, depressive symptoms, and general body-related distress compared to healthy controls, a phenomenon the authors likened to the “Sword of Damocles” effect, the persistent sense of threat hanging overhead.²⁹

Other research paints a more reassuring picture. A separate study found that the vast majority of patients viewed surveillance as beneficial, with 91% agreeing it was a good way to detect cancer and 82% saying it reduced their concern about developing pancreatic cancer. About 94% felt the advantages outweighed the disadvantages, and overall anxiety and depression scores were low.³⁰ The difference between these findings likely reflects who is being studied and how long they have been in surveillance. People who have been through multiple rounds of imaging tend to report more negative aspects, including sleeping worse and finding the follow-up process burdensome, compared to those just starting out.³⁰ A third study found that while some individual quality-of-life dimensions differed from the general population among IPMN patients, the clinical significance of those differences was questionable, and anxiety levels measured before and after surveillance visits did not differ meaningfully.³¹

The Microbiome Inside Pancreatic Cysts

A more surprising line of research has found that pancreatic cyst fluid is not sterile. It harbors a unique microbial community distinct from what is found in the gut or elsewhere in the body. One study identified 136 bacterial species in cyst fluid, including 17 that were both unusually abundant and had been previously linked to cancer-related processes in other organs.³² More recent work has started connecting specific bacteria to metabolic changes within the cyst. In mucinous cysts specifically, Streptococcus species appear to be associated with altered lipid metabolism that could promote cell growth, though the mechanistic picture is still being assembled.³³ This is early-stage research, and nobody is treating pancreatic cysts with antibiotics based on these findings. But the idea that the bacterial environment inside a cyst could influence whether it stays benign or turns malignant is a genuinely novel angle that could eventually reshape how risk is assessed.